EMCURE PHARMACEUTICALS L

NSE: EMCURE

Drug Manufacturers - Specialty & GenericHealthcareLARGE CAP•MCap ₹34.54k Cr

₹1,820.60₹-15.40 (-0.84%)

Market Closed • NSE

Market cap₹34.54k Cr

Enterprise value₹36.22k Cr

P/E TTM34.13

Forward P/E23.42

P/B6.97

EPS TTM₹53.35

Forward EPS₹77.72

D/E0.31

Dividend yield0.00%

52W high₹2,100.70

52W low₹1,306.50

Price chart(1Y)

1Y Return:+4.86% (+₹84.40)

H: ₹2,100.7L: ₹1,679

1W-2.51%

1M-4.67%

3M-5.40%

6M+13.72%

1Y+35.11%

Today at a glance

Day range

₹1,816.20₹1,849.30

52 week range

₹1,306.50₹2,100.70

Volume39.6K0.22x 20D avg

Free float50.00%-77.90% volume

EMCURE PHARMACEUTICALS L closed at INR1820.60 (-0.84%) on volume 0.22x its 20-day average, trading 13.33% below its 52-week high.

Technical analysis

RSI (14)34.8Neutral (30–70)

MACDBEARISHBearish (Below signal)

ATR (14)₹54.90High

SMA 20₹1,918.42BEARISH

SMA 50₹1,917.01BEARISH

SMA 100₹1,868.41BEARISH

SMA 200₹1,715.34BULLISH

CPR bottom₹1,858.50

Pivot₹1,851.00

CPR top₹1,843.50

What changed recently?

2026-Q2

Q2 FY2026 Financial Results

PAT moved +20.8% QoQ

2026-09-04

DIVIDEND Announced

Dividend - Rs 3.60 Per Share

2025-08-14

DIVIDEND Announced

Dividend - Rs 3 Per Share

Shariah audit

Methodology: AAOIFI Shariah Standard No. 21

PASS4/4 criteria

Shariah Compliant

Criteria	Numerator	Denominator	Value	Threshold	Status
Interest-bearing debt ratio	₹1.52k Cr	₹34.54k Cr	4.40%	≤ 33%	PASS
Non-halal income ratio	–	₹9.20k Cr	0.00%	≤ 5%	PASS
Illiquid assets ratio	₹9.48k Cr	₹9.61k Cr	98.58%	≥ 20%	PASS
Receivables ratio	–	₹9.61k Cr	—	≤ 49%	PASS

Valuation & sector context

MetricCompanySector

P/E34.1337.00

Forward P/E23.42—

P/B6.975.00

EV/EBITDA—18.00

PEG—1.00

Earnings yield2.902.70

Growth & profitability

RevenuePAT

FY23PAT margin 9.00%

FY24PAT margin 7.60%

FY25PAT margin 8.60%

FY26PAT margin 10.00%

Revenue and PAT bars use independent scales to make their year-on-year direction readable.

Revenue CAGR 3Y+5.20%

Revenue CAGR 5Y+9.20%

PAT CAGR 3Y+10.70%

PAT CAGR 5Y+11.70%

Operating margin15.44%

Net margin10.45%

Financial health & cash flow

Net debt₹1.38k CrModerate

Interest coverage9.60xEBIT / interest

CFO / PAT1.12x3Y average

Net debt / EBITDA—Leverage

Operating cash flow₹943.5 Cr

Capital expenditure–

Free cash flow₹395.9 Cr

Financial statements

Complete reported financial history · Values use the company's reporting currency

Hover over the chart for exact reported values. Percentage lines use the right-hand axis.

Fundamental scorecard

Overall65/100

Valuation50/100

Profitability50/100

Financial health95/100

A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.

Strengths, risks & investment thesis

Strengths

Low Debt Profile: Debt-to-Equity is comfortable at 0.31x

High Cash Flow Conversion: CFO/PAT averaged 1.12x over last 3 years

Risks

Subject to cyclical raw material and macro industry pressures

Bull case

Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.

Bear case

Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.

Flip condition

Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.

Corporate Action

Complete dividend, bonus, split, rights and other action history

Record date	Corporate action	Information	Announcement date	Ex-date
04 Sept 2026	Dividend	₹3.60 / share	—	04 Sept 2026
14 Aug 2025	Dividend	₹3.00 / share	—	14 Aug 2025

Delivery participation

Traded volume and delivery percentage across the latest 20 sessions

Average delivery (20D)54.47%-0.93% latest vs average

Highest delivery83.35%on 06 Oct

Average volume (20D)179.3KTrading-session average

Conviction trendWeakening-0.93% latest reading

Traded volumeDelivery %

Peer comparison

Compare valuation, latest quarterly performance and year-on-year growth

8 companies

Company name	Market cap ₹ Cr	P/E ratio	Dividend yield %	Quarterly sales ₹ Cr	Profit after tax ₹ Cr	Sales growth %	Profit growth %
Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis	₹4.22L	34.90	0.91%	₹15,300.00	₹2,901.00	+10.46%	+26.52%
Divi's Laboratories LimitedDIVISLAB Open analysis	₹2.43L	82.97	0.33%	₹3,080.00	₹902.00	+27.80%	+65.50%
Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis	₹1.73L	72.83	0.83%	₹4,128.00	₹389.00	+41.90%	-21.89%
Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis	₹1.13L	54.32	0.25%	₹7,044.00	₹610.00	+20.58%	+38.32%
Zydus Lifesciences LimitedZYDUSLIFE Open analysis	₹1.12L	25.03	0.09%	₹8,017.00	₹990.00	+21.95%	-34.91%
LENSKART SOLUTIONS LTDLENSKART Open analysis	₹1.12L	174.73	0.00%	₹2,714.00	₹228.00	+43.29%	+273.77%
Laurus Labs LimitedLAURUSLABS Open analysis	₹1.11L	101.83	0.12%	₹2,026.31	₹367.60	+29.10%	+125.49%
Cipla LimitedCIPLA Open analysis	₹1.07L	31.78	0.98%	₹7,119.00	₹786.00	+2.33%	-39.16%

About EMCURE PHARMACEUTICALS L

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.

IndiaHealthcare

Questions investors ask

Is EMCURE PHARMACEUTICALS L Shariah compliant?

EMCURE PHARMACEUTICALS L is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (4.4%) complies with AAOIFI threshold (≤ 33%).

What is EMCURE PHARMACEUTICALS L's current valuation relative to peers?

EMCURE PHARMACEUTICALS L trades at a P/E of 34.1x compared to the sector median of 37x, and a Price-to-Book of 7.0x.

Is the company financially healthy?

The company has a Debt-to-Equity ratio of 0.31x. Interest coverage is 9.6x.

What are the historical revenue and profit growth rates?

Over the past 5 years, revenue compounded at 9.2% while net profit growth averaged 11.7%.

Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.

Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.